DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $2.57B
• Dividend Yield: 5.17%
• Average Volume (3M): 3.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -5.78%
• EPS Growth: -445.83%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.52
• Shares Outstanding: 199,483,860
• 10 Day Avg. Volume: 3,260,616
• 30 Day Avg. Volume: 3,010,927
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 13.73
• Enterprise Value/Market Cap: 2.06
• Enterprise Value/Revenue: 1.43
• Enterprise Value/Gross Profit: 2.76
• Enterprise Value/Ebitda: -9.20
• 1Y Price Target: $16.46
• Price Target Upside: 33.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 16

• Rating: 54 Neutral
• Price Target: $15.00 ▲(21.26% Upside)

DENTSPLY SIRONA's overall stock score reflects significant financial challenges, with declining revenues and profitability weighing heavily. Technical indicators suggest a bearish trend, and valuation concerns persist due to negative earnings. However, the earnings call provided some positive insights into operational improvements, and recent corporate events may enhance strategic positioning.

Positive Factors

Strategic Retention of Wellspect

Retaining Wellspect, a leader in continence care, strengthens Dentsply Sirona's portfolio with its strong product pipeline and market potential, supporting long-term growth.

DS Core Platform Growth

The growing user base of the DS Core platform indicates increasing adoption of digital solutions, enhancing Dentsply Sirona's competitive edge in dental technology.

Adjusted EBITDA Margin Expansion

Improved EBITDA margins reflect successful cost reduction efforts, enhancing profitability and operational efficiency, which are crucial for long-term financial health.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in maintaining market share and sales growth, which could impact future profitability and market positioning.

Impairment Charges

Significant impairment charges suggest potential overvaluation of assets, impacting financial statements and indicating challenges in certain business segments.

Impact of Tariffs

Increased tariff costs pressure profitability and may necessitate strategic adjustments, affecting long-term cost management and competitive pricing.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.

How the Company Makes Money

DENTSPLY SIRONA generates revenue through multiple streams, primarily from the sale of dental equipment and consumables. Their core revenue comes from the manufacturing and distribution of dental imaging systems, including X-ray machines and digital imaging software, which are sold to dental practices and clinics. Additional revenue is derived from dental materials and supplies, such as restorative materials and orthodontic products. The company also benefits from recurring revenue through the sale of maintenance services and software upgrades for their imaging systems. Strategic partnerships with dental professionals, educational institutions, and other healthcare providers enhance their distribution network and market presence, contributing to their overall earnings. The company's commitment to innovation and product development further positions it to capitalize on emerging trends in dental technology, thereby expanding its revenue potential.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA is encountering financial challenges, with declining revenues and profitability evidenced by negative margins and net losses. The balance sheet is moderately stable, but negative ROE is concerning. Positive cash flow management provides some support amidst these challenges.

Income Statement

The income statement shows declining revenue and profitability. The TTM (Trailing-Twelve-Months) data indicates a negative net profit margin of approximately -24.4% and a gross profit margin of 51.6%. The company has experienced a negative revenue growth rate of -0.5% compared to the previous year. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet reflects moderate stability with a debt-to-equity ratio of 1.2, indicating a balanced leverage. The equity ratio stands at approximately 33.2%, showing a reasonable proportion of equity financing. Return on Equity (ROE) is negative due to recent losses, which is a concern for potential investors.

Cash Flow

Cash flow analysis shows positive operating cash flow with an operating cash flow to net income ratio of approximately -0.49, indicating operating efficiencies despite net losses. Free cash flow growth rate is slightly negative, but free cash flow to net income ratio is positive, suggesting effective cash management relative to earnings challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.72B	3.79B	3.96B	3.92B	4.25B	3.34B
Gross Profit	1.92B	1.96B	2.09B	2.13B	2.36B	1.66B
EBITDA	-576.00M	-518.00M	232.00M	-677.00M	972.00M	336.00M
Net Income	-908.00M	-910.00M	-132.00M	-950.00M	411.00M	-83.00M
Balance Sheet
Total Assets	6.05B	5.75B	7.37B	7.64B	9.22B	9.34B
Cash, Cash Equivalents and Short-Term Investments	398.00M	272.00M	334.00M	365.00M	339.00M	438.00M
Total Debt	2.42B	2.27B	2.30B	2.09B	2.24B	2.41B
Total Liabilities	4.04B	3.81B	4.08B	3.83B	4.18B	4.37B
Stockholders Equity	2.01B	1.94B	3.29B	3.81B	5.04B	4.97B
Cash Flow
Free Cash Flow	278.00M	281.00M	228.00M	368.00M	515.00M	548.00M
Operating Cash Flow	443.00M	461.00M	377.00M	517.00M	657.00M	635.00M
Investing Cash Flow	-171.00M	-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
Financing Cash Flow	-165.00M	-302.00M	-307.00M	-329.00M	-379.00M	490.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Negative. The current price of 12.37 is below the 20-day moving average (MA) of 13.66, below the 50-day MA of 14.23, and below the 200-day MA of 15.84, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 28.51 is Positive, neither overbought nor oversold. The STOCH value of 3.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	79 Outperform	40.15B	28.84	23.47%	0.82%	9.84%	37.48%
BDX	70 Outperform	53.33B	33.46	6.30%	2.30%	7.86%	14.24%
HOLX	69 Neutral	14.77B	27.30	11.50%	―	1.28%	-17.73%
COO	67 Neutral	13.59B	32.93	4.88%	―	6.35%	12.94%
XRAY	54 Neutral	$2.57B	―	-37.78%	5.17%	-5.78%	-445.83%
BAX	54 Neutral	11.59B	-81.77	-9.32%	3.13%	-27.41%	67.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

DENTSPLY SIRONA Corporate Events

Dentsply Sirona Retains Wellspect Healthcare After Review

On September 8, 2025, Dentsply Sirona announced the completion of its strategic review of the Wellspect Healthcare business, deciding to retain it within its portfolio. This decision follows extensive evaluation and outreach, concluding that Wellspect, a leader in the global continence care market, will deliver greater financial and strategic benefits to stockholders as part of Dentsply Sirona, given its strong product pipeline and market potential.

Dentsply Sirona Appoints New CEO Daniel T. Scavilla

On July 21, 2025, Dentsply Sirona announced the appointment of Daniel T. Scavilla as President and Chief Executive Officer, effective August 1, 2025, succeeding Simon D. Campion. Mr. Scavilla brings extensive experience from his previous roles at Globus Medical and Johnson & Johnson, where he held various leadership positions. The company also released select preliminary financial results for the second quarter of 2025, expecting net sales of approximately $935 million and adjusted earnings per share between $0.50 and $0.52. This leadership transition and financial update are part of Dentsply Sirona’s ongoing efforts to enhance value for shareholders and position itself as a leader in the dental market.

DENTSPLY SIRONA Issues $550M Junior Subordinated Notes

On June 12, 2025, DENTSPLY SIRONA Inc. issued $550 million in Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055, with an interest rate of 8.375% per year until 2030, and thereafter adjusted based on the Five-year U.S. Treasury Rate plus a spread, ensuring it does not fall below the initial rate. The proceeds from this issuance were partially used to repay and terminate the company’s $435 million Bridge Loan Facility, resulting in no early termination penalties or prepayment premiums, which may positively impact the company’s financial stability and operational flexibility.